Henderson Clark M, Lutsey Pamela L, Misialek Jeffrey R, Laha Thomas J, Selvin Elizabeth, Eckfeldt John H, Hoofnagle Andrew N
Department of Laboratory Medicine and.
Division of Epidemiology and Community Health.
Clin Chem. 2016 Jan;62(1):179-87. doi: 10.1373/clinchem.2015.244541. Epub 2015 Oct 9.
Vitamin D deficiency is associated with poor bone health and other adverse health outcomes; however, the associations are greatly attenuated in black vs white individuals. One possible explanation for this attenuation is different concentrations of bioavailable vitamin D metabolites in plasma, which are estimated with equations that include the total concentration of vitamin D binding globulin (VDBG) and haplotype-specific dissociation constants.
We developed a method to quantify VDBG with LC-MS/MS that could also identify the haplotypes/isoforms of VDBG present. We validated the method according to recent recommendations for publications of biomarker studies. We determined serum VDBG concentrations in samples from the Atherosclerosis Risk in Communities cohort and compared the results with a widely used monoclonal immunoassay.
With 10 μL of serum or plasma, the lower limit of quantification for the assay (<20% CV) was 71 μg/mL. The assay was linear from 62 to 434 μg/mL, with total imprecision of 7.3-9.0% CV at approximately 250 μg/mL. Significant hemolysis interfered with quantification. The identification of isoforms was 97% concordant with genotyping (κ coefficient). Method comparison with immunoassay revealed significant isoform-specific effects in the immunoassay. Mean concentrations (SD) of VDBG by mass spectrometry were similar in whites and blacks [262 (25) vs 266 (35) μg/mL, respectively; P = 0.43].
Validated mass spectrometric methods for the quantification of proteins in human samples can provide additional information beyond immunoassay. Counter to prior observations by immunoassay, VDBG concentrations did not vary by race.
维生素D缺乏与骨骼健康不佳及其他不良健康结局相关;然而,在黑人与白人个体中,这种关联程度大幅减弱。这种减弱的一种可能解释是血浆中生物可利用维生素D代谢物浓度不同,这些浓度通过包含维生素D结合球蛋白(VDBG)总浓度和单倍型特异性解离常数的方程来估算。
我们开发了一种用液相色谱 - 串联质谱法(LC - MS/MS)定量VDBG的方法,该方法还能识别存在的VDBG单倍型/异构体。我们根据生物标志物研究发表的最新建议对该方法进行了验证。我们测定了社区动脉粥样硬化风险队列样本中的血清VDBG浓度,并将结果与广泛使用的单克隆免疫测定法进行比较。
使用10μL血清或血浆时,该测定法的定量下限(<20%变异系数)为71μg/mL。该测定法在62至434μg/mL范围内呈线性,在约250μg/mL时总不精密度为7.3 - 9.0%变异系数。显著溶血会干扰定量。异构体的鉴定与基因分型的一致性为97%(κ系数)。与免疫测定法的方法比较显示免疫测定法中存在显著的异构体特异性效应。通过质谱法测定的白人和黑人VDBG平均浓度(标准差)相似[分别为262(25)μg/mL和266(35)μg/mL;P = 0.43]。
经过验证的用于定量人类样本中蛋白质的质谱方法可以提供免疫测定法之外的额外信息。与免疫测定法先前的观察结果相反,VDBG浓度不因种族而异。